181 related articles for article (PubMed ID: 28287015)
1. Cost-consequence analysis of two different active flowable hemostatic matrices in spine surgery patients.
Makhija D; Rock M; Ikeme S; Kuntze E; Epstein JD; Nicholson G; Price JS; Patel V
J Med Econ; 2017 Jun; 20(6):606-613. PubMed ID: 28287015
[TBL] [Abstract][Full Text] [Related]
2. Cost-consequence analysis of different active flowable hemostatic matrices in cardiac surgical procedures.
Makhija D; Rock M; Xiong Y; Epstein JD; Arnold MR; Lattouf OM; Calcaterra D
J Med Econ; 2017 Jun; 20(6):565-573. PubMed ID: 28097913
[TBL] [Abstract][Full Text] [Related]
3. Cost-consequence analysis of a hemostatic matrix alone or in combination for spine surgery patients.
Ramirez MG; Niu X; Epstein J; Yang D
J Med Econ; 2018 Oct; 21(10):1041-1046. PubMed ID: 30112922
[TBL] [Abstract][Full Text] [Related]
4. Similar patient outcomes yet different hospital costs between flowable hemostatic agents.
David G; Lim S; Gunnarsson C; Kocharian R; Roy S
J Med Econ; 2015; 18(9):735-45. PubMed ID: 25907200
[TBL] [Abstract][Full Text] [Related]
5. Observational evaluation of outcomes and resource utilization from hemostatic matrices in spine surgery.
Price JS; Tackett S; Patel V
J Med Econ; 2015; 18(10):777-86. PubMed ID: 25934148
[TBL] [Abstract][Full Text] [Related]
6. Floseal only versus in combination in spine surgery: a comparative, retrospective hospital database evaluation of clinical and healthcare resource outcomes.
Ramirez MG; Deutsch H; Khanna N; Cheatem D; Yang D; Kuntze E
Hosp Pract (1995); 2018 Oct; 46(4):189-196. PubMed ID: 29986148
[TBL] [Abstract][Full Text] [Related]
7. Real-world economic and clinical outcomes associated with current hemostatic matrix use in spinal surgery.
Danker W; Kelkar SS; Marston XL; Aggarwal J; Johnston SS
J Comp Eff Res; 2022 Dec; 11(17):1231-1240. PubMed ID: 36306241
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of hemostatic matrices in cardiac surgery.
Tackett SM; Calcaterra D; Magee G; Lattouf OM
J Cardiothorac Vasc Anesth; 2014 Dec; 28(6):1558-65. PubMed ID: 25245578
[TBL] [Abstract][Full Text] [Related]
9. Prospective, randomized, controlled clinical trial of a novel matrix hemostatic sealant in children undergoing adenoidectomy.
Mathiasen RA; Cruz RM
Otolaryngol Head Neck Surg; 2004 Nov; 131(5):601-5. PubMed ID: 15523433
[TBL] [Abstract][Full Text] [Related]
10. Gelatin Paste as an Alternative Cost-Effective Hemostatic Agent in Cranial Surgery: Doing More with Less.
Serrato-Avila JL; Navarro-Fernández JO; Hernández-Reséndiz R; Cacho-Díaz B; Reyes-Soto G; Monroy-Sosa A
World Neurosurg; 2019 Feb; 122():224-228. PubMed ID: 30415038
[TBL] [Abstract][Full Text] [Related]
11. Hospital economic impact from hemostatic matrix usage in cardiac surgery.
Tackett SM; Sugarman R; Kreuwel HT; Alvarez P; Nasso G
J Med Econ; 2014 Sep; 17(9):670-6. PubMed ID: 24927164
[TBL] [Abstract][Full Text] [Related]
12. Use of a flowable haemostat versus an oxidised regenerated cellulose agent in primary elective cardiac surgery: economic impact from a UK healthcare perspective.
Joshi MR; Latham J; Okorogheye G
J Cardiothorac Surg; 2017 Nov; 12(1):107. PubMed ID: 29187216
[TBL] [Abstract][Full Text] [Related]
13. FLOSEAL Versus SURGIFLO in Lumbar Surgery: Similar Outcomes, Different Costs in a Matched Cohort Analysis.
Ye IB; Thomson AE; Smith RA; Pease TJ; Chowdhury N; Donahue J; Miseo V; Jauregui JJ; Cavanaugh DL; Koh EY; Ludwig SC
World Neurosurg; 2023 Jun; ():. PubMed ID: 37356481
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Security, and Manageability of Gelified Hemostatic Matrix in Bleeding Control during Thoracic and Lumbar Spine Surgery: FloSeal versus Surgiflo.
Landi A; Gregori F; Marotta N; Delfini R
J Neurol Surg A Cent Eur Neurosurg; 2016 Mar; 77(2):139-43. PubMed ID: 26351870
[TBL] [Abstract][Full Text] [Related]
15. Gelatin-thrombin hemostatic matrix in neurosurgical procedures: hemostatic effectiveness and economic value of clinical and surgical procedure-related benefits.
Esposito F; Cappabianca P; Angileri FF; Cavallo LM; Priola SM; Crimi S; Solari D; Germanò AF; Tomasello F
J Neurosurg Sci; 2020 Apr; 64(2):158-164. PubMed ID: 27456032
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of floseal compared to nasal packing for the management of anterior epistaxis.
Le A; Thavorn K; Lasso A; Kilty SJ
Laryngoscope; 2018 Aug; 128(8):1778-1782. PubMed ID: 29314035
[TBL] [Abstract][Full Text] [Related]
17. An In Vivo Comparison of Hemostatic Gelatin Matrix Products in a Porcine Spleen Biopsy-punch Model.
Hutchinson RW; Werrlein S; Johns DB; Zhang G; Clymer JW; Kocharian R
Surg Technol Int; 2015 Nov; 27():53-7. PubMed ID: 26680379
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative anaphylaxis secondary to intraosseous gelatin administration.
Luhmann SJ; Sucato DJ; Bacharier L; Ellis A; Woerz C
J Pediatr Orthop; 2013; 33(5):e58-60. PubMed ID: 23752162
[TBL] [Abstract][Full Text] [Related]
19. Use of Floseal®, a human gelatine-thrombin matrix sealant, in surgery: a systematic review.
Echave M; Oyagüez I; Casado MA
BMC Surg; 2014 Dec; 14():111. PubMed ID: 25528250
[TBL] [Abstract][Full Text] [Related]
20. Prospective, randomized clinical trial of the FloSeal matrix sealant in cardiac surgery.
Nasso G; Piancone F; Bonifazi R; Romano V; Visicchio G; De Filippo CM; Impiombato B; Fiore F; Bartolomucci F; Alessandrini F; Speziale G
Ann Thorac Surg; 2009 Nov; 88(5):1520-6. PubMed ID: 19853105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
